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Abstract 
Background: The blood–brain barrier (BBB) ensures central nervous system (CNS) homeostasis by strictly controlling 
the passage of molecules and solutes from the bloodstream into the CNS. Complex and continuous tight junctions 
(TJs) between brain endothelial cells block uncontrolled paracellular diffusion of molecules across the BBB, with clau-
din-5 being its dominant TJs protein. However, claudin-5 deficient mice still display ultrastructurally normal TJs, sug-
gesting the contribution of other claudins or tight-junction associated proteins in establishing BBB junctional com-
plexes. Expression of claudin-12 at the BBB has been reported, however the exact function and subcellular localization 
of this atypical claudin remains unknown.
Methods: We created claudin-12-lacZ-knock-in C57BL/6J mice to explore expression of claudin-12 and its role in 
establishing BBB TJs function during health and neuroinflammation. We furthermore performed a broad standardized 
phenotypic check-up of the mouse mutant.
Results: Making use of the lacZ reporter allele, we found claudin-12 to be broadly expressed in numerous organs. 
In the CNS, expression of claudin-12 was detected in many cell types with very low expression in brain endothelium. 
Claudin-12lacZ/lacZ C57BL/6J mice lacking claudin-12 expression displayed an intact BBB and did not show any signs of 
BBB dysfunction or aggravated neuroinflammation in an animal model for multiple sclerosis. Determining the precise 
localization of claudin-12 at the BBB was prohibited by the fact that available anti-claudin-12 antibodies showed com-
parable detection and staining patterns in tissues from wild-type and claudin-12lacZ/lacZ C57BL/6J mice.
Conclusions: Our present study thus shows that claudin-12 is not essential in establishing or maintaining BBB TJs 
integrity. Claudin-12 is rather expressed in cells that typically lack TJs suggesting that claudin-12 plays a role other 
than forming classical TJs. At the same time, in depth phenotypic screening of clinically relevant organ functions of 
claudin-12lacZ/lacZ C57BL/6J mice suggested the involvement of claudin-12 in some neurological but, more promi-
nently, in cardiovascular functions.
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Introduction
The endothelial blood–brain barrier (BBB) in the central 
nervous system (CNS) microvessels protects the CNS 
from changes in the blood, thus ensuring CNS homeo-
stasis, which is a prerequisite for proper function of CNS 
neurons. The anatomical basis of the BBB is represented 
by unique intercellular tight junctional (TJs) complexes 
formed between BBB endothelial cells, inhibiting paracel-
lular diffusion of water-soluble molecules [1, 2]. In addi-
tion to sealing the paracellular pathway, BBB endothelial 
cells keep out unwanted compounds from the brain by 
their lack of fenestrae and low pinocytotic activity [3]. To 
meet the high demand of the neuronal cells for energy 
and to drive efflux of toxic metabolites from the CNS, 
BBB endothelial cells express unique combinations of 
enzymes and transporters [4].
The TJs of the BBB are distinct from those of other 
endothelial cells with respect to their high complexity 
and continuity of junctional strands that rather resem-
ble those of the epithelial cells [5]. Freeze fracture studies 
demonstrated that in contrast to the peripheral vascula-
ture, which shows predominantly E-face associated TJs, 
TJs of the BBB are mainly P-face associated [6]. P-face 
association of TJs-strands has been shown to correlate 
with barrier properties of the BBB [7]. Additionally, the 
protein expression signature at the TJs is very unique, 
being composed of occludin, junctional adhesion mol-
ecules and members of the claudins family [2]. The clau-
dins are integral membrane proteins exclusively found 
in the TJs of all epithelia and endothelial cells, and they 
are essential and sufficient in establishing TJs and thus 
paracellular diffusion barriers [8]. In mammals, there are 
presently 27 known members of the claudin family, which 
exert different functions and present tissue and devel-
opmental stage specific expression patterns [9]. Thus, 
a different combination of claudins establishes specific 
TJs, which ultimately regulates their tightness [10]. It is 
known that some claudins can tighten the cleft between 
two adjacent cells, such as claudin-1 and claudin-3 [11, 
12], while others form paracellular pores that contrib-
ute to a controlled passage of ions and water through 
the TJs, e.g. claudin-2 and claudin-16 [13, 14]. However, 
for some claudins, a precise function is not yet known. 
In the BBB endothelium, it was suggested that claudin-3, 
claudin-5 and claudin-12 contribute to the tightness of 
this barrier [15]. Claudin-5 is the most predominant 
claudin expressed in the BBB TJs and is essential for the 
establishment of BBB TJs during development, since its 
absence leads to perinatal death of mice due to increased 
permeability of the BBB to small molecular tracers [15, 
16]. Moreover, with an inducible knock-down mouse 
model, it was seen that suppression of claudin-5 in 
the TJs leads to the disruption of BBB integrity and 
ultimately to seizures and behavioral changes [17], which 
demonstrates the importance of claudin-5 in the mainte-
nance of this paracellular barrier in the adult. However, 
claudin-5-deficient mice display morphologically intact 
TJs suggesting the presence of other proteins localized to 
BBB TJs. Claudin-3 was described to be involved in the 
induction and maintenance of the BBB [18, 19]. How-
ever, expression of claudin-3 at the BBB TJs has been 
repeatedly questioned [20, 21] and more recently, its 
absence from the BBB endothelium was confirmed by 
employing a combination of methods including immu-
nostaining, Western Blotting and single cell RNAseq 
analysis (scRNAseq) of the brain endothelium [1, 22]. 
scRNAseq of brain endothelial cells has also confirmed 
lack of expression of the TJ sealing claudin-1 at the BBB, 
as previously described [4, 22–24]. As claudin-5 by itself 
induces E-face associated TJs this has raised the question 
if another member of the claudin family could contrib-
ute to the formation of P-face associated TJs in the BBB 
[16]. Expression of claudin-12, an unusual member of 
the claudin family, has additionally been described at the 
BBB [15] and its expression in brain endothelial cells was 
recently confirmed by us [1]. Claudin-12 is an atypical 
member of the claudin family because it does not have 
a PDZ binding motif, which mediates the interaction of 
claudins with the cytoskeleton, by allowing the binding 
to the intracellular scaffolding proteins ZO-1, ZO-2 and 
ZO-3 [25]. Thus, its potential contribution to BBB TJs 
still remains unknown.
To answer this question, we generated a claudin-
12lacZ/lacZ C57BL/6J mouse, with a lacZ cassette inserted 
in the open reading frame (ORF) of claudin-12, which 
allows us not only to use it as a reporter gene for clau-
din-12 expression, but also to take advantage of the null 
allele to investigate the function of this protein. We 
observed broad expression of claudin-12 in numerous 
tissues and most prominently in smooth and striated 
muscle cells. Within the brain, expression of clau-
din-12 was detected in many different cell types with 
most prominent expression in neurons and astrocytes. 
Determining the subcellular localization of claudin-12 
protein was prohibited due to the lack of antibodies 
specifically and selectively detecting claudin-12 pro-
tein. Nonetheless, our study rules out an essential role 
for claudin-12 in regulating BBB integrity under non-
inflammatory or neuroinflammatory conditions, as we 
did not observe any aggravation of experimental auto-
immune encephalomyelitis (EAE), an animal model of 
multiple sclerosis (MS). Yet, an in-depth phenotypic 
study of the claudin-12lacZ/lacZ C57BL/6J mice points 
to possible roles of claudin-12 in select neurological 
functions and, more prominently, in cardiovascular 
functions.
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Materials and methods
Generation of claudin‑12lacZ/lacZ C57BL/6J mice
Three gene-targeted embryonic stem cell (ES) 
clones (Cldn12_13208A-A6, Cldn12_13208AE2 and 
Cldn12_13208AF12) from KOMP project number 
KO1756 were requested from the KOMP reposi-
tory at UC Davis. The mutation was generated on the 
Velocigen platform by Regeneron Pharmaceuticals 
(Tarrytown, NJ). The insertion of Velocigene cassette 
ZEN-Ub1 created a deletion of 760 bps between posi-
tions 5507663–5508422 of Chromosome 5 (Genome 
Build37) (J:136110). This deletion replaces the entire 
coding sequence residing only within in exon 5 with a 
lacZ cassette and a LoxP flanked neomycin-selection 
cassette. The deletion includes 28 bps upstream of 
the translational start site and 21  bps downstream of 
the stop codon. Parental ES cells are VGB6, which are 
derived from the C57BL/6NTac inbred mouse strain. 
The sequence of this allele is available here: https ://
www.i-dcc.org/imits /targ_rep/allel es/38187 /escel 
l-clone -genba nk-file. ES clone Cldn12_13208A-A6 
was injected into BALB/c blastocysts at the Institute 
of Laboratory Animal Science, University of Zurich. 
Five chimeric males were born and mated to C57BL/6J 
albino females. One of the chimeric males produced a 
single black male out of 40 offspring. The single black 
male was mated to C57BL/6J females and the off-
spring genotyped by PCR using the following primers: 
Cldn12_GT_SD (5′-CTC CTA GCC TCA TCC GAC TGA 
AAC G-3′), Cldn12_ ΔGT3_TDF (5′-CTG CTG TTC 
GTT TGG TAT TGT GCA TG-3′) and PGK 3′UTR FW1 
(5′-GGG TGG GAT TAG ATA AAT GCC TGC TCT-3′). 
PCR-cycling conditions were: 94  °C for 4 min., and 35 
repeats of 94 °C for 30 s., 62 °C for 30 s., 72 °C for 60 s., 
followed by 94 °C for 4 min. The wild-type (WT) allele 
was detected by a 586  bp band, while the neo-allele 
gave rise to a 775 bp band. To avoid any influence of the 
ubiquitin-C promoter driving the neomycin-resistance 
gene on the claudin-12 phenotype, the LoxP flanked 
neo-cassette was deleted by crossing claudin-12 neo 
heterozygous mice to ZP3-Cre (Tg(ZP3-cre)93Knw) 
mice expressing cre in the female germ line (oocytes) 
[26] (a gift from Pawel Pelczar). After deletion of the 
neo-cassette, claudin-12 mutated mice were genotyped 
by PCR using the following primers: Cldn12_FW2 
(5′-TTT CTG ATA GGA TGG GTA GGT GGT GG-3′), 
Cldn12_REV2 (5′-CAG GCC CGT GTA AAT CGT 
CAGGT-3′), LacZ-5′REV1 (5′-GAG CGA GTA ACA 
ACC CGT CGG ATT CT-3′). PCR-cycling conditions 
were: 94 °C for 4 min., and 35 repeats of 94 °C for 30 s., 
62  °C for 30  s., 72  °C for 60  s., followed by 94  °C for 
4  min. The WT allele was detected by a 425  bp band, 
while the claudin-12-lacZ-allele gave rise to a 607  bp 
band.
German Mouse Clinic
The claudin-12lacZ/lacZ mouse line was backcrossed to 
C57BL/6J four times prior to the German Mouse Clinic 
(GMC) Primary Screen. Health status was confirmed 
to be specific pathogen-free according to FELASA rec-
ommendations. Using the platform established at the 
GMC, we performed a primary phenotypic analysis of a 
total of 60 (15 mice each of each genotype and sex) [27–
29] exactly as described in the Additional file 6.
Mouse housing
Mice were housed in individually ventilated cages (IVC) 
under specific pathogen-free conditions at 22 °C and 55% 
relative humidity with free access to chow and water. 
Animal procedures executed were approved by the Vet-
erinary Office of the Canton Bern (permit no. BE55/09, 
BE42/14, BE72/15, BE31/17). At the GMC mice were 
maintained in IVC cages with water and standard mouse 
chow (Altromin no. 1314) according to the GMC housing 
conditions and German laws. All tests performed at the 
GMC were approved by the responsible authority of the 
district government of Upper Bavaria.
Experimental autoimmune encephalomyelitis (EAE)
Active EAE was induced in 8–12-week-old female clau-
din-12lacZ/lacZ C57BL/6J mice, claudin-12lacZ/+ C57BL/6J 
mice and their WT C57BL/6J littermates exactly as pre-
viously described [30, 31]. Weights and clinical disease 
activity were assessed twice daily and scored as follows: 
0, healthy; 0.5, limp tail; 1, hind leg paraparesis; 2, hind 
leg paraplegia; 3, hind leg paraplegia with incontinence 
implementing the 3R rules as described in [32]. Two 
independent experiments were performed.
Isolation of brain microvessels
Primary mouse brain microvessels were isolated from 
WT and claudin-12lacZ/lacZ C57BL/6J mice as previ-
ously described in detail [33]. The only modification to 
this previous protocol was that instead of the final plat-
ing step, microvessels were incubated in a red blood 
cell lysis buffer (0.83% ammonium chloride and Tris–
HCl, pH = 7.5), for 5  min, RT. After two washing steps, 
microvessels were lysed in HES lysis buffer (10  mM 
HEPES, 1 mM EDTA solution, 250 mM sucrose solution), 
in the presence of protease inhibitor cOmplete ULTRA 
Tablets, Mini, EDTA-free, EASYpack (1 tablet/10  mL) 
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(Roche Diagnostics, Mannheim, Germany), and kept at 
− 20 °C.
SDS‑PAGE
In accordance to the isolation of brain microvessels, mus-
cle tissue from WT and claudin-12lacZ/lacZ C57BL/6J mice 
was also lysed in HES lysis buffer (10 mM HEPES, 1 mM 
EDTA solution, 250  mM sucrose solution), in the pres-
ence of protease inhibitor cOmplete ULTRA Tablets, 
Mini, EDTA-free, EASYpack (1 tablet/10  mL) (Roche 
Diagnostics, Mannheim, Germany). Protein concen-
tration was measured using the Pierce™ BCA Protein 
Assay Kit (Thermo Scientific™ Pierce™ Protein Biol-
ogy, Waltham, USA), according to the manufacturer’s 
instructions. 20 μg of each sample were boiled at 95°, for 
5  min, and loaded onto a 10% SDS-polyacrylamide gel 
and transferred to a nitrocellulose membrane (Amer-
sham Protan, GE Healthcare, United Kingdom), using a 
Trans-Blot Turbo transfer system (BioRad Laboratories, 
Hercules, CA, USA), according to the manufacturer’s 
instructions. Membranes were blocked with Rockland 
Buffer (Rockland, Limerick, PA, USA) for 1 h at RT and 
incubated overnight at 4  °C with three different rabbit 
anti-mouse claudin-12 antibodies (IBL, cat. no 18801; 
Abcam cat. no ab107061; Invitrogen, cat. no 388200), 
mouse anti-mouse β-actin (Merck, cat. no A5316), rab-
bit anti-α-tubulin (Abcam, cat. no ab4074), rabbit anti-
claudin-5 (Thermo Fisher Scientific, cat. no 34-1600), 
rabbit anti-occludin (Thermo Fisher Scientific, cat. no 
71-1500), or rabbit anti-ZO-1 (Thermo Fisher Scien-
tific, cat. no 61-7300). On the following day, membranes 
were washed and incubated with secondary antibodies 
goat-anti-rabbit Alexa  Fluor® 680 (Thermo Fisher Sci-
entific, cat. No A21109) and goat anti-mouse  IRDye® 
TM 800 (Rockland Immunochemicals, cat. no 605-732-
125), for 1 h at RT. Proteins were detected by the Odys-
sey near infrared imaging system and software (LI-COR 
Biotechnology, Lincoln, NE, USA). Band intensity for the 
three independent experiments was quantified using the 
ImageJ software (NIH, Bethesda, MD, USA) and normal-
ized against β-actin.
Quantitative real‑time PCR analysis (qRT‑PCR)
RNA was extracted from the heart tissue of WT and 
claudin-12lacZ/lacZ C57BL/6J mice by using the High 
Pure RNA Isolation kit (Hoffman-La Roche, Basel, Swit-
zerland). cDNA was obtained from each sample’s total 
isolated RNA with the SuperScript III First-Strand Syn-
thesis System (Invitrogen, Carlsbad, CA, USA) and the 
qRT-PCR was done as previously described [4]. The 
pairs of primers that were used in this study are the fol-
lowing: 5′-CTG AGT TCA CTA AGC TGA CTT TGG -3′ 
(sense primer within exon 3) and 5′-CCT GTC TGC GCC 
TCT GAT -3′ (anti-sense primer within exon 4) for the 
5´prime untranslated region (UTR) of claudin-12 mRNA; 
5′-TGC TTG GAG AAA CGC TGA TT-3′ (sense primer 
within exon 4) and 5′-GTG GCT GCG TGG ACA TCT 
-3′ (anti-sense primer within the ORF integral to exon 
5) for the open reading frame (ORF); 5′-TGC TTG GAG 
AAA CGC TGA TT-3′ (sense primer within exon 4) and 
5′-GTC TGT CCT AGC TTC CTC ACTG-3′ for lacZ detec-
tion. ΔCT value was obtained (average  CT value of target 
gene − average  CT value of S16) and relative expression 
values of three independent experiments were calculated 
according to the comparative  2−ΔΔCt method (ΔΔCT = Δ 
 CT sample − Δ  CT WT).
LacZ staining of tissue sections
WT, Tie2-lacZ and claudin-12lacZ/+ C57BL/6J mice were 
anesthetized with Isoflurane Baxter (Arovet, Dietikon, 
Switzerland) and perfused with 1% paraformaldehyde 
(PFA). As positive controls, Tie2-lacZ (B6.FVB-Tg (TIE2-
lac)182Sato) transgenic mice were used [34]. Brain, ret-
ina, liver, heart, tongue, skeletal muscle, intestine and 
kidney were removed, washed twice in PBS (pH = 7.4) 
and fixed with 1% PFA + 5  mM EDTA + 2  mM  MgCl2, 
for 4  h at 4  °C. The tissue was next incubated in 18% 
sucrose, overnight at 4  °C, prior to embedding in Tis-
sue-Tek O.C.T. compound (Sakura Finetek, The Nether-
lands) and snap-freezing [35]. 20  µm cryosections were 
cut from these tissues, air dried at RT for 4 h, and fixed 
in 1% PFA + 5  mM EDTA + 2  mM  MgCl2 for 3  min. 
Afterwards, a rehydration step was performed with PBS 
(pH = 7.4). For LacZ staining, sections were incubated 
overnight with 0.1% X-Gal at 37 °C in the dark. Next, sec-
tions were washed once in distilled water, incubated for 
1 min in 1% Neutral Red (Sigma-Aldrich, St. Louis, Mis-
souri, USA) and differentiated in distilled water. Then, 
cryosections were dehydrated in consecutive steps in 
EtOH 75%, EtOH 85%, EtOH 95% and EtOH 100%, and 
finally in Xylol before mounting in  Entellan® (Merck Mil-
lipore, Darmstadt, Germany). Three independent experi-
ments were performed and were analysed using a Nikon 
Eclipse E600 microscope connected to a Nikon Digi-
tal Camera DXM1200F with the Nikon NIS-Elements 
BR3.10 software (Nikon, Egg, Switzerland). Images were 
processed and mounted using Adobe Illustrator software 
(Adobe Systems, CA, USA).
Immunofluorescence staining of tissue sections
WT and claudin-12lacZ/lacZ C57BL/6J mice were anesthe-
tized with Isoflurane Baxter (Arovet, Dietikon, Switzer-
land) and perfused with 1% PFA. Brains and liver were 
removed, embedded in Tissue-Tek® OCT compound 
(Sakura Finetek, The Netherlands) and snap-frozen. 
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Cryosections were cut at 6  μm or 10  μm thickness and 
fixed in either ice cold acetone or 2% PFA for 10 min and 
air-dried. Cryosections were stained as described before 
[36, 37]. Sections were incubated for 1  h, RT, with the 
following primary antibodies: two different rabbit anti-
mouse claudin-12 antibodies (IBL, cat. no 18801; Invitro-
gen, cat. no 388200), rat anti-PECAM-1 (in house, clone 
Mec13.3), rabbit anti-β-galactosidase (Thermo Fisher Sci-
entific, cat. no A-11132), rat anti-CD140b (eBioscience, 
cat. no 14-1402-82), mouse anti-GFAP (Sigma-Aldrich, 
cat- no G3893), mouse anti-NeuN (clone A60, Millipore, 
cat. no MAB377), rabbit anti-fibronectin (DAKO, cat. no 
A0245) and biotinylated goat anti-mouse IgG (Vector, 
cat. no BA-9200). After the washing steps, the sections 
were incubated with the following secondary antibod-
ies: goat polyclonal IgG Cy3 anti-rabbit (Jackson Immu-
noResearch, cat. no 11-165-144), donkey anti-rat IgG 
(H+L) Alexa Fluor 488 (Thermo Fisher Scientific, cat. 
no A-21208), donkey anti-rabbit IgG (H+L) Alexa Fluor 
488 (Thermo Fisher Scientific, cat. no A-21206), donkey 
anti-mouse IgG (H+L) Alexa Fluor 488 (Thermo Fisher 
Scientific, cat. no A-32766), Streptavidin-Cy3 (Vector, 
cat. no SA-1300) and with DAPI (1:1000, Thermo Fisher 
Scientific, Carlsbad, CA, USA), for 1 h, RT. Fluorescence 
stainings were performed in at least three independent 
experiments and were analysed using a Nikon Eclipse 
E600 microscope connected to a Nikon Digital Camera 
DXM1200F with the Nikon NIS-Elements BR3.10 soft-
ware (Nikon, Egg, Switzerland). Images were processed 
and mounted using Adobe Illustrator software (Adobe 
Systems, CA, USA).
Statistics
Statistical analysis was performed using GraphPad Prism 
6.0 software. To compare two groups, an unpaired t-test 
with Welch’s correction was performed. For the analy-
sis of the EAE experiments, a Mann–Whitney U-test 
was performed. Results are shown as mean ± SD and a 
p < 0.05 was considered significant. If not stated other-
wise, data generated by the German Mouse Clinic was 
analyzed using R (Version 3.2.3). Tests for genotype 
effects were made by using t-test, Wilcoxon rank sum 
test, linear models, or ANOVA and posthoc tests, or 
Fisher’s exact test depending on the assumed distribution 
of the parameter and the questions addressed to the data. 
A p-value < 0.05 has been used as level of significance; a 
correction for multiple testing has not been performed.
Results
Generation of claudin‑12lacZ/lacZ C57BL/6J mice
Insertion of the Velocigene cassette ZEN-Ub1 within the 
claudin-12 gene created a deletion of 760 bps. This dele-
tion replaces most of exon 4, including the entire open 
reading frame (ORF) of claudin-12, with a lacZ cassette 
(Fig. 1a). Gene targeting was performed in VGB6 ES cells 
(derived from C57BL/6NTac mice) and correct targeting 
was assessed employing the Velocigen platform, includ-
ing genotyping by quantitative PCR to verify loss of a 
claudin-12 WT allele (Velocigene citation). Injection of 
claudin-12-targeted ES cells into BALB/c blastocysts 
and consecutive embryo transfer gave rise to 5 chimeric 
males, one of which allowed for germ line transmission 
of the mutated claudin-12 allele. Heterozygous F1 mice 
were produced by mating with C57BL/6J females. Het-
erozygous offspring were mated to Zp3-Cre mice to 
remove the floxed neo-cassette. The claudin-12lacZ/+ mice 
were further backcrossed to C57BL/6J.
To further confirm the deletion of the claudin-12 ORF 
after insertion of the lacZ cassette and based on the his-
tochemical analysis described below, we performed 
a transcript analysis by qRT-PCR of heart samples of 
WT and claudin-12lacZ/lacZ C57BL/6J mice (Fig.  1b). 
As expected, we observed that both WT and claudin-
12lacZ/lacZ C57BL/6J heart samples had transcripts for the 
upstream region of the ORF and while in WT C57BL/6J 
mice the presence of the ORF was detected, in claudin-
12lacZ/lacZ C57BL/6J mice this was not the case (Fig. 1b). 
LacZ was only detected in claudin-12lacZ/lacZ C57BL/6J 
heart samples, confirming the successful insertion of the 
lacZ cassette in the claudin-12 ORF (Fig. 1b). As a next 
step, we then looked at the viability of the claudin-12lacZ/
lacZ C57BL/6J mice. Interestingly, claudin-12lacZ/lacZ mice 
survived to weaning age at less than the expected Men-
delian ratio (17.2%) (Table 1). Nonetheless, adult mutant 
mice were fertile and healthy. No difference in the mor-
tality of adult claudin-12 null mice versus WT littermates 
was observed.
Claudin‑12 is expressed in many organs including the CNS
Taking advantage of the lacZ reporter gene in our clau-
din-12lacZ/+ C57BL/6J mouse line, we investigated clau-
din-12 expression in tissue sections from several organs 
of the mouse including liver, heart, kidney, intestine, 
skeletal muscle, tongue, retina and the brain, by analyz-
ing β-galactosidase activity with the chromogenic sub-
strate X-gal by histochemistry. We detected prominent 
β-galactosidase activity in skeletal muscle cells and car-
diac myocytes, as well as in smooth muscle cells of the 
tongue and the intestine, suggesting an important role of 
claudin-12 in muscular function. Furthermore, epithelial 
cells in the kidney and the intestine as well as hepatocytes 
in the liver showed prominent β-galactosidase staining 
(Additional file 1).
To determine if claudin-12 is expressed at the BBB, we 
investigated β-galactosidase activity in brain sections 
from claudin-12lacZ/+ C57BL/6J mice compared to WT 
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mice, as a negative control, and of Tie2-lacZ mice, as con-
trol for β-galactosidase activity in endothelial cells [34]. 
As expected, no β-galactosidase activity was detected 
in the WT brain tissue (Fig. 2). In the brain tissue from 
Tie2-lacZ mice, we detected abundant β-galactosidase 
activity in the endothelial cells of the vasculature in the 
Fig. 1 Claudin-12 targeting strategy in C57BL/6J mice. a Schematic representation of the knock-out strategy. The open reading frame of claudin-12 
is located in exon 5 and is targeted by a BAC-based targeting vector that contains an expression and neomycin-selection cassettes. In the targeted 
allele, a deletion of 760 bps is present, which removes the entire coding sequence. Arrows indicate LoxP sites surrounding the selection cassette 
that are targeted by Cre recombinase. b Relative expression of different regions of the claudin-12 gene in heart muscle samples isolated from WT 
and claudin-12lacZ/lacZ C57BL/6J mice was assessed by qRT-PCR. For each region of the gene, technical triplicates in three independent experiments 
were measured. Relative quantification is represented by the  2−ΔΔCt value. Cldn12 claudin-12, UTR untranslatable region, ORF open reading frame, 
n.d. not detectable
Table 1 Claudin-12 genotype ratios of mice at weaning age, with the total number of mice obtained per genotype (WT, 
claudin-12lacZ/+ and claudin-12lacZ/lacZ) and per sex, with the corresponding percentage
Claudin‑12 genotype Mice weaned Female mice Male mice
# % # % # %
WT 102 27.4 52 13.9 50 13.4
lacZ/+ 206 55.4 103 27.7 103 27.7
lacZ/lacZ 64 17.2 24 6.5 40 10.8
Total 372 100 179 48.1 193 51.9
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brain parenchyma and the meninges, as well as in the 
choroid plexus as reported previously [34] (Fig.  2). In 
contrast, brain tissue sections from claudin-12lacZ/+ 
C57BL/6J mice did not show any endothelial cell specific 
β-galactosidase activity. We rather observed a character-
istically punctate pattern of β-galactosidase activity in 
numerous cells in the CNS throughout the entire brain 
parenchyma, in the meninges, in the choroid plexus, 
and also in retinal tissue (Fig.  2 and Additional file  2). 
At the same time, β-galactosidase activity was visible in 
the smooth muscle cell layer of larger vessels in the brain 
parenchyma as well as in the meninges, but we did not 
detect any specific lacZ activity in the endothelial cells of 
these larger vessels or in endothelial cells of microvessels 
forming the BBB (Fig. 2). Our data shows that claudin-12 
expression in the CNS is not restricted to the vasculature 
and that vascular expression seems to be more promi-
nent in smooth muscle cells or pericytes than in the 
endothelial cells per se. At this point, we took advantage 
of a publicly available datasets of single-cell transcrip-
tomics of all the major vascular and vessel-associated 
cell types from the adult mouse brain (http://betsh oltzl 
ab.org/Vascu larSi ngleC ells/datab ase.html) [22, 38] and 
of bulk RNA datasets from purified neurons, astrocytes, 
microglia, endothelial cells, pericytes, and oligodendro-
cytes from mouse cortex [24], and looked at occurrence 
of claudin-12 mRNA. These datasets show low amounts 
of claudin-12 mRNA expression in the brain of mice, 
in cells such as pericytes, oligodendrocytes, vascular 
smooth muscle cells, astrocytes, fibroblasts and neurons 
and endothelial cells of the vasculature. Thus, our detec-
tion of β-galactosidase activity in numerous cells in the 
brain (Fig. 2) is in accordance to these previous findings.
We next aimed to localize claudin-12 expression to 
specific cells in the brain tissue. Taking advantage of an 
antibody recognizing β-galactosidase, we performed 
immunofluorescence stainings on brain sections and 
confirmed that β-galactosidase staining was absent from 
brain tissue sections from WT C57BL/6J mice, but again 
detectable throughout the brain tissue from claudin-
12lacZ/lacZ C57BL/6J mice (Fig.  3 and Additional file  3). 
We detected positive immunostaining for β-galactosidase 
in rare PECAM-1-positive endothelial cells and in few 
PDGFRβ-positive pericytes (Fig. 3 and Additional file 3). 
At the same time, β-galactosidase staining was more fre-
quently localized in GFAP-positive astrocytes and most 
Fig. 2 Claudin-12 expression in the CNS. Immunohistochemical staining of frozen brain sections from WT, Tie2-lacZ and claudin-12lacZ/+ C57BL/6J 
mice for β-galactosidase activity (blue), with examples of the cortex, meninges and choroid plexus. Three independent stainings were done. Boxed 
areas are shown in higher magnification. Scale bars = 10 μm and 50 μm, as indicated
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abundant in NeuN-positive neurons in the cortex, in the 
hippocampus and in the cerebellum (Fig.  3 and Addi-
tional file  3). Taken together, our data show that clau-
din-12 is expressed at low levels in different CNS cell 
types and is mainly expressed by astrocytes and neurons.
Lack of reagents to detect expression and localization 
of claudin‑12 protein
Since we could not readily identify prominent clau-
din-12 expression in brain endothelial cells by detection 
of lacZ reporter activity, we attempted to identify clau-
din-12 protein expression by immunostaining in brain 
tissue sections from WT and claudin-12lacZ/lacZ C57BL/6J 
mice. We used three different commercially available 
Fig. 3 Claudin-12 is expressed by different cell types in the CNS. Immunofluorescence staining of frozen brain sections from WT and claudin-12lacZ/
lacZ C57BL/6J mice, for β-galactosidase (red) and endothelial cells (PECAM-1), pericytes (PDGFRβ), astrocytes (GFAP) and neurons (NeuN) (green), 
in the brain cortex. Nuclei are stained with DAPI (blue). Boxed areas are shown in higher magnification. β-gal stands for β-galactosidase. Scale 
bars = 10 and 50 μm, as indicated. Two independent series of stainings were performed
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anti-claudin-12 antibodies, and obtained contradictory 
results. In fact, the antibody from IBL detects endothe-
lial claudin-12 in brain sections of WT but also in mutant 
mice (Additional file  4A), while the antibody from Inv-
itrogen failed to produce any positive immunostaining 
for claudin-12 in brain tissues in both (data not shown). 
We then tried to detect claudin-12 in liver sections, to 
test the suitability of the available antibodies in a tissue 
where high expression of claudin-12 was observed by us 
(Additional file  1). As observed for the brain, we found 
the antibody from IBL to detect claudin-12 in the liver 
of WT and mutant mice, while the one from Invitro-
gen completely failed to stain claudin-12 in both tissues 
(Additional file  4B). Finally, we aimed to detect clau-
din-12 protein expression by SDS-PAGE to completely 
exclude that the contradictory results are not due to 
technical issues. Thus, besides the samples from brain 
microvessels from WT and claudin-12lacZ/lacZ C57BL/6J, 
we also used samples from skeletal muscle from WT and 
claudin-12lacZ/lacZ C57BL/6J mice as a control, since it is 
one of the organs that showed very high β-galactosidase 
activity. Using the same antibodies as before, we again 
obtained inconclusive results, since we did not detect any 
band for claudin-12 in both WT and in the claudin-12lacZ/
lacZ brain microvessel samples with any of the antibodies 
(Fig.  4a). However, in the samples from skeletal muscle 
we detected a 22  kDa band in both, the WT samples, 
but also in the claudin-12lacZ/lacZ samples (Fig.  4b). This 
set of results suggests that the available antibodies fail to 
detect the low expression levels of claudin-12 protein in 
CNS blood vessels from WT mice. At the same time, our 
observations underscore the available claudin-12 anti-
bodies do not allow for specific detection of claudin-12 
by Western Blot, which is most likely due to a cross-
reactivity with another claudin, as we detected a band of 
comparable size to claudin-12 in the skeletal muscle of 
the claudin-12lacZ/lacZ samples, which lack expression of 
claudin-12.
Absence of claudin‑12 does not affect BBB integrity 
nor aggravate EAE
Despite the low expression levels of claudin-12 detected 
in this study, we next asked if lack of claudin-12 expres-
sion will affect composition and integrity of BBB TJs. To 
this end, we first analyzed expression of tight junction-
associated proteins in brain microvessels from WT 
or from claudin-12lacZ/lacZ C57BL/6J healthy mice. We 
detected no difference in the protein expression levels 
of claudin-5, occludin and ZO-1 in freshly isolated brain 
microvessles from claudin-12lacZ/lacZ C57BL/6J versus 
WT mice (Fig. 5). To study a potential role of claudin-12 
in the BBB during neuroinflammation we next took 
advantage of the animal model of MS, EAE, that mimics 
two major pathological hallmarks for MS, namely BBB 
breakdown and immune cell infiltration. TJ disruption 
contributes to BBB dysfunction in MS and is well mim-
icked in EAE [23, 39], and thus, we induced active EAE 
in WT and claudin-12lacZ/lacZ C57BL/6J mice. No signifi-
cant difference was found between WT and mutant mice 
when looking at onset of the clinical disease, the disease 
incidence (99% in WT and claudin-12lacZ/lacZ mice) and 
the overall disease severity as measured as the area under 
the curve for WT and claudin-12lacZ/lacZ C57BL/6J mice 
(Fig. 6a, b). Thus, lack of claudin-12 did not aggravate the 
development of EAE.
Fig. 4 Lack of reagents allowing to detect expression of claudin-12 protein. Immunoblot analysis of claudin-12 protein levels in freshly isolated 
brain microvessels (a) and in skeletal muscle (b) from WT and claudin-12lacZ/lacZ C57BL/6J mice, using three different polyclonal anti-claudin-12 
antibodies. Three independent immunoblots for both skeletal muscle and brain microvessels were analysed
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To determine if absence of claudin-12 nevertheless 
affects BBB integrity, in healthy conditions and dur-
ing EAE, we performed an immunofluorescence stain-
ing for endogenous vascular tracers, namely fibronectin 
and mouse IgG (Fig.  6c). Under healthy conditions, we 
did not detect any immunostaining for fibronectin or 
mouse IgG beyond the confines of the brain parenchy-
mal vasculature in WT and claudin-12lacZ/lacZ C57BL/6J 
mice (Fig.  6c). On the other hand, we found significant 
leakage for both vascular molecules into the brain tis-
sue in mice suffering from EAE, as expected (Fig. 6c). At 
the same time and in accordance to the clinical disease 
course we did not observed any apparent differences in 
the amount of leakage of fibronectin or mouse IgG across 
the BBB between WT and claudin-12lacZ/lacZ C57BL/6J 
mice (Fig.  6c). Taken together, these data underscore 
that in the C57BL/6J mouse claudin-12 does not play an 
essential role in maintaining BBB integrity in health or 
neuroinflammation.
To determine if claudin-12 may play a different role in 
BBB function as compared to regulating TJ integrity we 
investigated if claudin-12 expression was upregulated 
under inflammatory conditions. To this end, we induced 
EAE in WT and claudin-12lacZ/+ C57BL/6J mice and col-
lected brain tissue at the peak of the disease (day 17). 
We then performed histochemistry in brain sections 
from these mice and analysed β-galactosidase activ-
ity using the chromogenic substrate X-gal. As expected, 
Fig. 5 Absence of claudin-12 does not affect the expression of tight junction proteins in brain microvessels. Immunoblot analysis and 
quantification of the protein levels of claudin-5, occludin and ZO-1 in freshly isolated brain microvessels from WT and claudin-12lacZ/lacZ C57BL/6J 
mice. Bar graphs show mean ± SD of two independent experiments
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lacZ staining was only visible at the level of the cortex in 
heterozygous animals, while the WT littermates did not 
show any traces of staining (Fig. 6d). Nonetheless, when 
we compared claudin-12 expression in animals that did 
not develop any disease phenotype (score 0) to animals 
that reached a clinical score of 2, there was no difference 
in the observed staining (Fig. 6d). Therefore, we can con-
clude that under neuroinflammatory conditions, clau-
din-12 expression is not upregulated.
Phenotyping of claudin‑12lacZ/lacZ C57BL/6J mice
As the next step, and by acknowledging the broad expres-
sion observed for claudin-12 in a diverse range of organs, 
we submitted the claudin-12lacZ/lacZ C57BL/6J mice to 
a systematic multiparameter phenotypic analysis per-
formed by the German Mouse Clinic (Helmholtz Centre 
Munich). The specific aim of this study was to understand 
if lack of claudin-12 in the CNS leads to neurological 
alterations independent from BBB maintenance or if lack 
of claudin-12 in other organs would affect entirely differ-
ent physiological functions. Thus, a standardized pheno-
typic analysis of a total of 30 WT mice (15 of each sex) 
and 30 claudin-12lacZ/lacZ C57BL/6 mice (15 of each sex) 
was performed at the age of 10 to 21  weeks, determin-
ing over 550 different parameters in the areas of behavior, 
neurology, the eye, steroid metabolism, bone and carti-
lage, nociception, clinical chemistry and hematology, 
immunology, allergy, pathology, cardiology and molecu-
lar phenotyping. Overall, we found several phenotypic 
changes in claudin-12lacZ/lacZ C57BL/6J mice compared to 
controls. An overview table of the results can be found in 
Additional file 5 and the results are summarized in Addi-
tional File 6 and published at the GMC phenomap (https 
://www.mouse clini c.de). In the context of understanding 
potential roles of claudin-12 in the CNS, it is interesting 
to note that analysis of basic behavioral and motor func-
tions in the Open Field assay showed decreased loco-
motor activity in claudin-12lacZ/lacZ C57BL/6J mice and 
decreased anxiety in female claudin-12lacZ/lacZ C57BL/6J 
mice. Assessment of auditory function did not show 
significant alterations but only minor changes in auditory 
brain stem response or acoustic startle reflex. Interest-
ingly, while showing normal retinal thickness, both male 
and female claudin-12lacZ/lacZ C57BL/6J mice showed sig-
nificantly reduced axial eye lengths compared to controls.
Beyond phenotypic changes associated with the CNS 
we found female but not male mutants presented with 
alterations in energy metabolism and in cardiovascu-
lar functions. In contrast, male but not female mutants 
showed increased body weight when compared to 
controls and increased absolute and normalized liver 
and spleen weights. Taken together claudin-12lacZ/lacZ 
C57BL/6J mice displayed a number of mostly subtle phe-
notypic changes, which in part were sex specific and cor-
relate to the ubiquitous expression of claudin-12 found in 
this study.
Discussion
The BBB plays a crucial role in maintaining CNS home-
ostasis, by preventing free diffusion of solutes into the 
brain, with the BBB TJs playing an essential role in seal-
ing the paracellular cleft between the BBB endothelial 
cells. The claudin family of TJs proteins are crucial in 
establishing and maintaining TJ function at the BBB [2]. 
During recent years, there is an increasing understanding 
of the role of each individual claudin in contributing to 
tissue specific TJ functions [40]. Thus, to understand BBB 
TJ function it is essential to understand which claudins 
are expressed in brain endothelial cells and localized to 
BBB TJs. Bearing in mind the important role each claudin 
plays in maintaining barrier function under physiological 
conditions and how disturbance of their localization at 
the TJs can contribute to barrier breakdown, it is urgent 
to fully clarify the molecular claudin makeup of BBB TJs. 
Claudin-5 is the most enriched claudin in the vascular 
endothelium of the BBB. Its absence is associated with 
BBB integrity breakdown, an early feature in the develop-
ment of MS [41], and it is also implied in the pathology of 
stroke, traumatic brain injury and schizophrenia [17, 42]. 
However, it was seen that claudin-5 knock-out mice still 
present morphologically intact TJs [16]. As claudins are 
Fig. 6 Absence of claudin-12 does not affect BBB integrity nor aggravate the development of EAE. a Graph of the clinical disease course of one 
representative  MOGaa35-55 induced aEAE in WT (black line; n = 11) and claudin-12lacZ/lacZ C57BL/6J mice (blue line; n = 11) is shown. Average disease 
scores ± SEM as assessed twice daily are shown. b Disease severity determined by the area under the curve (AUC) and analyzed until day 55. Bar 
graphs represent the mean ± SD of two independent experiments including 21 WT and 21 claudin-12lacZ/lacZ C57BL/6J mice. c Immunofluorescence 
staining for fibronectin (green) and mouse IgG (red) on frozen brain sections from WT and claudin-12lacZ/lacZ C57BL/6J is shown. Upper row—
healthy mice, lower row mice suffering from EAE. Two independent stainings were performed. Scale bar = 50 μm. d Immunohistochemical 
staining of frozen brain sections from WT and claudin-12lacZ/+ C57BL/6J mice after induction of aEAE. β-galactosidase (blue) staining can be seen in 
examples of the cortex, cerebellum and choroid plexus. Animals with score 0 were induced with aEAE but did not develop any clinical symptom, 
whereas animals with score 2 presented hindleg paraplegia. Three independent stainings were done. Scale bar = 50 μm
(See figure on next page.)
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essential and sufficient for TJ induction this means that 
another claudin that is present at the BBB TJs contributes 
to TJs formation in the absence of claudin-5. In the past 
years, claudin-1 and claudin-3 were repeatedly suggested 
to be part of the BBB TJs [3, 18]. However, our recent 
studies have shown that these claudins are not expressed 
in brain endothelial cells and can thus not contribute 
to BBB TJs [1, 23]. Claudin-12 is an additional claudin, 
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expression of which has been described in BBB TJs [15]. 
Claudin-12 is an unusual claudin, lacking a PDZ binding 
motif in its C-terminal domain, which is required to con-
nect claudins via scaffolding proteins such as ZO-1 to the 
cytoskeleton [25]. The possible function of claudin-12 at 
the BBB has remained unknown to date.
To tackle this question, in the present study we cre-
ated claudin-12lacZ/+ and claudin-12lacZ/lacZ C57BL/6J 
mice allowing to explore claudin-12 expression as well 
as the impact of claudin-12 deletion on BBB TJ integ-
rity. Making use of the lacZ reporter allele, we found 
a characteristic punctate β-galactosidase activity in 
numerous cells throughout the entire CNS. Our find-
ings are in accordance to the staining pattern previously 
observed by the International Mouse Phenotyping Con-
sortium (IMPC) when analysing reporter gene expres-
sion of a lacZ allele of different claudin-12 mutant mice 
 (Cldn12tm1b(EUCOMM)Wtsi) by whole mount lacZ staining 
of adult  Cldn12tm1b(EUCOMM)Wtsi mice (http://www.mouse 
pheno type.org/data/searc h/impc_image s?kw=%22cld 
n12%22). This previous dataset thus underscores ubiq-
uitous expression of claudin-12 throughout the brain 
and furthermore shows that claudin-12 expression is 
enriched in the grey matter of the spinal cord.
In our present study, vascular expression of claudin-12 
based on β-galactosidase activity was clearly visible in 
the smooth muscle cell layer of larger vessels in the brain 
parenchyma, as well as in the meninges rather than in the 
endothelial cells of these vessels. In turn, it could be spe-
cifically detected by endothelial-cell-specific lacZ activ-
ity in Tie2-lacZ reporter mice. Furthermore, we failed to 
detect lacZ activity in endothelial cells of microvessels 
forming the BBB in our brain tissue sections. This sug-
gests that if claudin-12 is expressed in brain endothe-
lial cells, this is at a very low level. This observation was 
confirmed by our immunofluorescence stainings, which 
allowed to localize expression of the β-galactosidase 
reporter in sparse PECAM-1-positive brain endothelial 
cells and few PDGFRβ-positive pericytes. At the same 
time, positive immunostaining for the β-galactosidase 
reporter was found in GFAP-positive astrocytes and most 
abundantly in NeuN-positive neurons further underscor-
ing low but ubiquitous expression of claudin-12 in the 
brain of the mouse.
In fact, previous scRNAseq transcriptomic analy-
sis of brain vessels isolated from developing (P7) and 
adult mice confirms low levels of expression of clau-
din-12 mRNA in a wide range of vascular and CNS ves-
sel associated cell types (https ://markf sabba gh.shiny 
apps.io/vectr db/ and http://betsh oltzl ab.org/Vascu larSi 
ngleC ells/datab ase.html) [22, 38, 43]. Average reads for 
claudin-12 mRNA were found to be low and similar in 
endothelial cells along the vascular tree and were found 
to be higher in smooth muscle cells compared to brain 
endothelial cells. In addition, low expression of clau-
din-12 was also detected in microglial cells, oligoden-
drocytes, astrocytes and neurons [22, 24] (http://www.
brain rnase q.org/). Last but not least, brain endothelial 
expression levels of claudin-12 were found compara-
ble to those detected using the same methodology in 
lung endothelial cells. Our present observations under-
score low to undetectable expression of claudin-12 in 
brain endothelium and visible expression in vascular 
smooth muscle cells, pericytes, astrocytes and neurons. 
As these cells do not typically form TJs, this suggests 
that claudin-12 plays a role other than forming classical 
TJs. Expression data on claudin-12 mRNA in isolated 
brain microvessels and the detected regulation of clau-
din-12 mRNA expression must therefore be carefully 
interpreted as it may reflect regulation of claudin-12 
expression in pericytes, smooth muscle cells or even 
in astrocytes, rather than the brain endothelial cells 
proper [44].
To determine the subcellular localization of claudin-12 
in the CNS vasculature we made use of commercially 
available antibodies to claudin-12 and performed side-
by-side immunostainings on brain sections of WT and 
claudin-12lacZ/lacZ C57BL/6J mice. We could not observe 
any difference in the staining patterns produced by the 
anti claudin-12 antibodies in the brain sections of WT 
and claudin-12lacZ/lacZ C57BL/6J mice. This observa-
tion therefore prohibits reliable subcellular localization 
of claudin-12 in the CNS vasculature and suggests that 
antibodies recognizing claudin-12 cross-react with other 
molecules present in CNS microvessels. Cross-reactiv-
ity of claudin-12 detecting antibodies was confirmed by 
Western Blots, which showed detection of a similar sized 
band in tissue samples from claudin-12lacZ/lacZ C57BL/6J 
mice.
In light of our previous observations that claudin-3 
targeting antibodies produce an identical staining pat-
tern in CNS microvessels in claudin-3 deficient and 
WT C57BL/6J mice [1], it seems that claudin-targeting 
antibodies often produce false-positive detection of the 
respective claudin due to cross-reactivity with other clau-
dins, which may be due to the highly conserved nature 
of the immunogenic domains of this family of proteins 
[45]. Employing presently available claudin-12 antibod-
ies we could therefore not reproduce the prominent 
immunostaining for claudin-12 originally observed at the 
BBB in mice when using a home-made anti-claudin-12 
antibody [15]. Lack of reliable antibodies detecting clau-
din-12 thus also questions previous observations of clau-
din-12 protein expression in the human brain endothelial 
cell line hCMEC/D3 [46]. However, significant expres-
sion of claudin-12 mRNA has also been detected in this 
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cell line [47]. At the same time, transcriptome profiling 
of freshly isolated cells from the human brain (avail-
able at http://www.brain rnase q.org) shows even lower 
expression levels for claudin-12 mRNA in human brain 
endothelial cells as observed in the mouse, but at the 
same time confirms expression of claudin-12 in cells 
other than brain endothelium in the CNS [48]. Thus, the 
final confirmation if claudin-12 is expressed at the pro-
tein level in CNS blood vessels and if so its precise cel-
lular and subcellular localization within the CNS vascular 
cells in mouse and man remains to be determined.
In accordance to the available transcriptome pro-
files on brain cells [22, 24], we observed that claudin-12 
is expressed in various cells of the brain vasculature as 
well as in astrocytes and neurons. Thus, a functional 
impact of claudin-12 in the settings of neuroinflamma-
tion remains possible. We therefore hypothesized that its 
absence could still affect BBB integrity. BBB breakdown 
is a major hallmark of MS and is associated with loss of 
TJs (summarized in [2]). It has previously been shown 
that impaired BBB integrity, e.g. in PECAM-1-deficient 
mice, aggravates EAE [49], while endothelial cell-specific 
ectopic expression of claudin-1 inhibits BBB breakdown 
during EAE and ameliorates chronic disease [23]. There-
fore, we here compared development of clinical EAE in 
claudin-12lacZ/lacZ C57BL/6J mice to that in their WT lit-
termates. We did not observe any differences in clinical 
EAE between WT and claudin-12lacZ/lacZ C57BL/6J mice. 
We also did not detect any differences in BBB integrity or 
immune phenotype, e.g. upregulation of adhesion mol-
ecules in claudin-12lacZ/lacZ C57BL/6J mice versus WT 
C57BL/6J mice during EAE. Thus, although claudin-12 
is expressed in various cells of the CNS including vascu-
lar cells, its absence does not affect BBB integrity during 
autoimmune neuroinflammation.
Conclusions about claudin-12 expression in the present 
study rely on available mRNA data sets [22, 24, 38] and 
on the novel information provided in the present study 
based on claudin-12 lacZ reporter gene expression. Our 
present observations on claudin-12 expression using our 
claudin-12 reporter mouse allowed for robust detec-
tion of β-galactosidase staining in various tissues, such 
as skeletal muscle, liver, intestine and kidney, suggesting 
that while claudin-12 is expressed in different cells of the 
CNS, its expression is stronger in the periphery. These 
findings are consistent with the previous observations on 
claudin-12 expression in the  Cldn12tm1b(EUCOMM)Wtsi mice 
(http://www.mouse pheno type.org/data/searc h/impc_
image s?kw=%22cld n12%22).
Due to the presence of claudin-12 in a wide range of 
organs, we decided to perform a systematic multipa-
rameter phenotypic analysis of our claudin-12lacZ/lacZ 
C57BL/6J mouse and compare it to WT littermates.
The mutant mice showed some behavioral impair-
ments. While it is currently not possible to draw 
conclusions concerning the exact nature of these 
alterations, our findings are bolstered by the reported 
behavioral changes in the aforementioned IMPC line 
(Cldn12tm1b(EUCOMM)Wtsi). Although there are dif-
ferences between the two lines and the observed effects 
are subtle, behavioral alterations now described in both 
suggest that loss of claudin-12 likely affects brain func-
tion to some degree, most probably due to its lack of 
expression in neurons. It is therefore of interest to bet-
ter understand the potential role of claudin-12 in the dif-
ferent cells of the brain. Claudin-12 has in addition been 
shown to be expressed in the inner ear as well as well as 
in retina, as confirmed by us in the present study [50, 51]. 
Thus, the subtle alterations in auditory and retinal func-
tion might also be interesting for further analysis. More-
over, it is important to highlight that some morphological 
and functional alterations of the heart were detected in 
claudin-12lacZ/lacZ C57BL/6J mice in the cardiovascular 
screen. Here, additional studies are required to elucidate 
the role and functional implications of claudin-12 in the 
murine cardiac muscle. Also, the fact that claudin-12 is 
strongly expressed in skeletal muscle and is reported to 
be involved in vitamin D-dependent calcium absorption 
[52] asks for further clarifications in the role of this pro-
tein in the muscle, although under standard conditions 
no changes have been detected for muscle function ana-
lyzed by grip strength.
Conclusion
In summary, with this study we suggest that claudin-12 
expression is detectable, but low, in brain endothelial 
cells. Expression of claudin-12 is observed in additional 
cells of the vasculature like pericytes and in many cell 
types of the brain parenchyma, including astrocytes and 
neurons. Due to the lack of availability of antibodies reli-
ably detecting claudin-12, we could not determine pres-
ence and subcellular localization of claudin-12 protein 
in the microvascular endothelium. Claudin-12 expres-
sion in the CNS is not upregulated under inflammatory 
stimuli and its absence does not impair BBB integrity or 
aggravate the development of EAE. This suggests that 
claudin-12 is not required for maintaining BBB integrity. 
However, lack of claudin-12 promoted broad neurologi-
cal and behavioral changes, the exact mechanisms under-
lying this phenotype to be investigated.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
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Additional file 1. Claudin-12 expression in non-CNS tissue. Immunohis-
tochemical staining for β-galactosidase, in blue, in frozen sections from 
heart, skeletal muscle, tongue, liver, intestine and kidney, from WT and 
claudin-12lacZ/+ C57BL/6J mice. Three independent stainings were done. 
Scale bar = 100 μm. 
Additional file 2. Claudin-12 expression in CNS tissue. Immunohisto-
chemical staining for β-galactosidase activity (blue), in frozen sections 
from the eye of claudin-12lacZ/+ C57BL/6J mice and of a Tie2-lacZ mouse, 
as a positive control. Images show a similar detection of β-galactosidase 
activity in cells not associated with the vasculature in the brain cortex 
and in the retina of claudin-12lacZ/+ C57BL/6J mice. Arrows point to 
vessel associated staining in the brain of the claudin-12lacZ/+ C57BL/6J 
mouse and to endothelial cell specific staining in the Tie2-LacZ mouse. 
* highlights the typical punctate staining pattern for β-galactosidase 
activity in the brain. Boxed areas are shown in higher magnification. Three 
independent stainings were performed. Scale bars = 10 and 50 μm, as 
indicated. 
Additional file 3. Claudin-12 is expressed by different CNS cell types. 
Multi-color immunofluorescence staining of frozen brain sections from 
WT and claudin-12lacZ/lacZ C57BL/6J mice, for β-galactosidase in red and 
PECAM-1 (endothelial cells), PDGFRβ (pericytes), GFAP (astrocytes) and 
NeuN (neurons) in green, in the hippocampus and cerebellum. Nuclei are 
stained with DAPI (blue). β-gal stands for β-galactosidase. Two independ-
ent stainings were done. Scale bar = 50 μm. 
Additional file 4. Lack of reagents allowing to localize expression of clau-
din-12 protein. (A) Immunofluorescence staining of frozen brain sections 
from WT and claudin-12lacZ/lacZ C57BL/6J mice with the anti-claudin-12 
antibody from IBL represented in green produces indistinguishable 
vascular and apparently junction associated staining in the brain tissues 
of both, WT and the claudin-12lacZ/lacZ C57BL/6J mice. Scale bar = 50 
μm. (B) Immunofluorescence staining of frozen liver sections from WT 
and claudin-12lacZ/lacZ C57BL/6J mice, using two different antibodies for 
claudin-12, represented in red. Notice how the antibody from IBL stains 
WT and claudin-12lacZ/lacZ tissue, while the anti-claudin-12 antibody from 
Invitrogen does not recognize claudin-12 in neither of the samples. Nuclei 
are stained with DAPI (blue). Three independent stainings were done. 
Scale bar = 100 μm. 
Additional file 5. Overview of tests performed by the German Mouse 
Clinic and summary of results.
Additional file 6. Complete phenotyping report of claudin-12lacZ/
lacZknock-in C57BL/6J mice.
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